Biotest AG / Key word(s): Legal Matter 04.11.2016 13:41 Disclosure of an inside information according to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR) Altered tax assessments for 2005-2008 lead to a decrease of claims against Biotest AG - proceedings against Biotest AG are close to be completed Dreieich, 4 November 2016. Today the Finanzamt Offenbach am Main (tax office Offenbach am Main) served to Biotest AG altered tax assessments for corporate tax, solidarity tax and trade tax for the years 2005 until 2008. The alterations relate to Biotest AG's Russia business. Compared to the tax assessments served on 3 August 2016, which has already been reported on by the company, there is a decrease in tax and interest expenses of EUR 6.9 million. Whereas the original total claim of the tax office had been EUR 21.4 million, the tax and interest expenses now come to a total of EUR 14.5 million Biotest AG accepts these altered tax assessments. Biotest is in advanced discussions with the investigative authorities as to the completion of the summary proceedings regarding a fine. The prosecutor has already applied for the fine at the responsible court. The liability resulting thereof in the amount of EUR 1.0 million was already included as a provision in the results as of 30 September 2016. In the meantime, the authorities discontinued the investigations against several defendants from Biotest AG. According to information from the authorities, discontinuations of further investigations will follow. The authorities still investigate against three of the company's managers. Based on these developments, the company assumes that no further significant negative effects for the company are to be expected from the Russian business. Biotest Aktiengesellschaft Board of Management Biotest AG Landsteinerstr. 5 D-63303 Dreieich www.biotest.de Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,400 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange. IR contact Dr. Monika Buttkereit phone: +49-6103-801-4406 email: [email protected] PR contact Dirk Neumüller phone: +49-6103-801-269 email: [email protected] Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.de Ordinary shares: securities' ID No. 522720; ISIN DE0005227201 Preference shares: securities' ID No. 522723; ISIN DE0005227235 Listing: Prime Standard Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart Contact: Dr. Michael Ramroth Chief Financial Officer Biotest AG Landsteinerstr. 3 63303 Dreieich Tel. +40 6103 801 338 Fax: +49 6103 801 347 [email protected] 04.11.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: [email protected] Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News-Service ---------------------------------------------------------------------------